New drug may cut transfusions for stem cell transplant patients
NCT ID NCT07450313
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if luspatercept can help people with blood cancers who have severe anemia after a stem cell transplant. The goal is to see if the drug reduces the need for red blood cell transfusions. About 20 adults aged 18-60 will take part. This is a phase 2 trial, meaning it is still being tested for safety and effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo reset the immune system to beat relapsed leukemia?
- AI platform aims to unlock Real-World cancer data on a massive scale
- 10,000 DNA samples could reveal hidden genetic triggers for leukemia and lymphoma
- Could a common arthritis drug shield transplant patients from a dangerous virus?
- New biologic MK-1045 targets Hard-to-Treat blood cancers
- Shorter chemo before transplant may cut severe side effects for blood cancer patients